Breast carcinoma with skin ulceration (SU) is considered a locally advanced disease.
| INTRODUCTION
It has been long thought that non-inflammatory skin involvement is a pathologic variable that places breast carcinoma (BC) in categories with most advanced loco-regional extent. 1 The most recent American Joint Committee on Cancer (AJCC) (2010) staging guidelines considered BC with skin ulceration (SU) vis a vis erosion as pT4b.
This designation would signify the tumor as a more advanced tumor stage of either IIIB or IIIC, depending upon the number of involved lymph nodes (IIIB when pN is 0, 1 or 2 and IIIC when pN is 3). 2 However, recent studies have suggested that T4 designation should be restricted to inflammatory carcinoma (T4d) only, with the consideration that T4 a, b, and c categories have outcomes similar to those in the T3 category, and substantially better than those with true inflammatory BC if carefully defined. [3] [4] [5] [6] [7] [8] In this situation, the other subcategories (T4a, T4b, and T4c) would then be categorized based on the size of the tumor in each case, regardless of skin or chest wall involvement. Although the AJCC task force acknowledged these studies, they did not change the staging system due to insufficient data to recommend this change at that time, but they did advocate further study and future consideration. depends upon other clinical, pathological or molecular factors. 9 We hypothesize that pathologists do not strictly follow the AJCC staging guidelines, particularly for relatively small tumors; tumor size correlates directly proportional to distant metastases; and SU may not be an independent factor in predicting worse clinical outcomes.
In order to examine these hypotheses, we pooled a large number of BC cases with SU treated in the adjuvant setting from different academic institutions and correlate with the clinical outcomes.
| ME TH ODS
In order to evaluate how the pathologists stage BC with SU, T-stage was abstracted from the original pathology report. To investigate if tumor size correlates directly proportional to distant metastases, tumor size was correlated with M-stage. Further, we attempted to investigate if tumor size plays a role in the disease free survival (DFS) and the overall survival (OS). In order to evaluate the role of SU in tumor behavior a subset from the clinical set designated as study cohort was clinically and pathologically matched with cases without SU, designated as matched cohort and survival outcomes were compared.
| Clinical set
The pathology database from each institution was searched using key words "breast," "carcinoma," "SU," "extending to skin," and "ero- regardless of the ratio. 11 There were 77 cases diagnosed using immunohistochemistry, 27 using FISH, and 7 had no HER2 assay performed.
| Study and matched cohorts
The study cohort is defined as a group of cases from the clinical set that has met certain inclusions criteria. Data analysis was performed using R version 3.2.1 (R Foundation, Vienna, Austria).
| Study cohort vs matched cohort
Fisher's test was used to examine the difference in the categorical parameters between the two groups, and logistic regression was used for the continuous parameters. OS and DFS were analyzed by KM methods to evaluate the survival difference between the two groups. Five-year probabilities for DFS and OS were also calculated.
3 | RESULTS
| Overall clinical set
In all included cases (n=111), the mean (range) of tumor size was 5. developed recurrence in the matched cohort. The 5-year DFS probability was 53% for the study cohort and 58% for the matched cohort; and for OS 75% for the study cohort and 84% for the matched cohort with no statistical significant difference. There was no statistical significant difference in the OS or DFS between the two cohorts. However, the survival had a trend towards worse DFS for patients with SU (Figure 1A,B) . Using different tumor size cutoffs (2.0-and 3.0-cm), there was no statistical significant difference between the two groups.
| Additional survival analyses
When the tumors were staged as T1, T2, or T3 ( Table 2 ). There was no statistical significant difference between these two stages for the OS (P=.265; Figure 5A ) but was significant for the DFS (P=.012; Figure 5B ).
In the univariate analysis (Table 4) Figure 6C ). Positive margins carry higher risk of tumor recurrence than negative margins (P<.0001; Figure 6D ). Higher number of positive lymph nodes carries higher risk of recurrence with borderline significance (P=.056; Figure 6E ).
None of the patients (n=13) who had a tumor size ≤1.7-cm died from disease with median (range) of follow up 54.5 (4, 108) months ( Figure 6F ). In the multivariate analysis none of the examined variables was statistically significant. This could result in administering a treatment with potential for multiple side effects without much benefit in decreasing a risk of recurrence for the patient. Similarly, in HER2 amplified carcinomas there is increasing evidence that relatively small tumors with no lymph node spread can be treated with less aggressive systemic CT.
T A B L E 2 Tumor staging based on reported T-stage, following AJCC guidelines, and independent from SU
14 Based on the current AJCC staging system, these relatively small ulcerating tumors would most certainly be treated more aggressively, therefore incurring the risk of more serious toxicities.
This study demonstrates the benefits of analyzing risk for a rare BC phenotype (eg, ulceration) across multiple institutions. Better 0  20  100  150  40  60  80  120   0  20  100  150  40  60  80  120   Months   T1  T2  T3   T1  T2  T3   T1  T2  T3   T1  T2 That is consistent with a previous study by G€ uth et al. 3 It is worth noting that many patients presented with locally advanced disease. Therefore, they underwent aggressive surgical procedures such as total mastectomy (90.1%) and axillary dissection (73%).
There have been few studies that investigated if there is a justification to categorize any non-inflammatory BC as pT4, such as clinical skin change including ulceration, skin nodules, or pathologic skin involvement. [3] [4] [5] [6] [7] [8] We intended to nullify all these variables except for pathology-proven SU, in order to evaluate if SU is an adverse factor and to investigate if these tumors should be staged It is worth noting that we did not perform our search for the candidate cases using a keyword "pT4" but we used "ulceration"/"erosion" keywords. That is in order to avoid selection bias and include all cases that had SU. Excluding the cases with relatively small tumor size from the National Cancer database would potentially influence the result of the study.
The AJCC staging system is a continuation of prior classification systems such as Columbia Clinical classification first published in 1943 by Haagensen and Stout. At that point in time BC with SU was more common and more homogenous as a group than the current time. 15 We found that BC with SU is a heterogeneous group mainly due to the wide range of tumor size, a factor we and others found to be significantly correlating with the clinical outcome. In conclusion, our data suggest that relatively small tumors with SU had an extent of disease similar to that observed in 
